Predict your next investment

HEALTHCARE | Drug Development
genocea.com

See what CB Insights has to offer

Founded Year

2006

Stage

IPO | IPO

Total Raised

$90.7M

Date of IPO

2/5/2014

Market Cap

0.06B

Stock Price

1.12

Revenue

$0000 

About Genocea Biosciences

Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. The company is working to create vaccines that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective and long-Aterm immunity against a wide array of diseases. Genocea designs vaccines using ATLAS, its technology platform. Genocea quickly identifies T cell antigens to induce broader and more powerful immune responses than existing vaccines. The company can recreate in vitro the T cell immune responses of hundreds of humans to thousands of potential antigens to identify a small number of proteins appropriate for testing as vaccine candidates.

Genocea Biosciences Headquarter Location

161 First Street

Cambridge, Massachusetts, 02139,

United States

617-876-8191

Latest Genocea Biosciences News

Genocea to Present at the Stifel 2021 Virtual Healthcare Conference

Nov 11, 2021

Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET. A live webcast of the presentation can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at  https://ir.genocea.com/events-presentations . A replay of the webcast will be archived for 90 days following the presentation. About Genocea Biosciences, Inc. Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com . Forward-Looking Statements This press release includes forward-looking statements related to GEN-011, GEN-009 and research updates within the meaning of the Private Securities Litigation Reform Act, including statements related to the anticipated timing of top-line results from Genocea’s Phase 1/2a clinical trial of GEN-011. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. These factors include, but are not limited to, risks related to the potential failure of our active product candidates which are in an early stage of clinical development; our ability to obtain regulatory approval for our current and future product candidates; potential delays in enrolling patients in our clinical trials; our reliance on third parties to conduct technical development, non-clinical studies and clinical trials for our product candidates; our reliance on third parties to conduct some or all aspects of our product manufacturing; our ability to obtain or protect intellectual property rights related to our product candidates; the potential impacts of COVID-19 on our business and financial results; changes in law, regulations, or interpretations and enforcement of regulatory guidance; our need for additional financing and the risks listed under "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2020 and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law. Investor Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Genocea Biosciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Genocea Biosciences in 1 CB Insights research brief, most recently on Dec 12, 2018.

Expert Collections containing Genocea Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genocea Biosciences is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Genocea Biosciences Patents

Genocea Biosciences has filed 18 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/16/2020

11/2/2021

Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/16/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/2/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Genocea Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Genocea Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.